Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Published byΣελήνη Κακριδής Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by."— Presentation transcript:

1 Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)  Eric L. Simpson, MD, Carsten Flohr, MD, PhD, Lawrence F. Eichenfield, MD, Thomas Bieber, MD, PhD, MDRA, Howard Sofen, MD, Alain Taïeb, MD, Ryan Owen, PhD, Wendy Putnam, PhD, Marcela Castro, MD, Kendra DeBusk, PhD, Chin-Yu Lin, PhD, Athina Voulgari, PhD, Karl Yen, MD, Theodore A. Omachi, MD  Journal of the American Academy of Dermatology  Volume 78, Issue 5, Pages e11 (May 2018) DOI: /j.jaad Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Proportion of atopic dermatitis patients achieving (A) a 50% reduction of Eczema Area and Severity Index, (B) a 75% reduction of Eczema Area and Severity Index, (C) an Investigator Global Assessment of 0 or 1, and (D) a 50% reduction of SCORing Atopic Dermatitis at week 12 of lebrikizumab treatment. Q4W, Every 4 weeks; SD, single dose. Journal of the American Academy of Dermatology  , e11DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Proportion of atopic dermatitis patients receiving lebrikizumab achieving (A) a 50% reduction of Eczema Area and Severity Index, (B) a 75% reduction of Eczema Area and Severity Index, (C) an Investigator Global Assessment of 0 or 1, and (D) a 50% reduction of SCORing Atopic Dermatitis over time. Q4W, Every 4 weeks; SD, single dose. Journal of the American Academy of Dermatology  , e11DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Adjusted mean percent change from baseline in (A) pruritus Visual Analog Scale, (B) sleep loss Visual Analog Scale, (C) Atopic Dermatitis Impact Questionnaire, and (D) Dermatology Life Quality Index over time in atopic dermatitis patients receiving lebrikizumab. Q4W, Every 4 weeks; SD, single dose. Journal of the American Academy of Dermatology  , e11DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

5 Supplemental Fig 1 Atopic dermatitis patient disposition for the TREBLE study. Q4W, Every 4 weeks; SD, single dose. Journal of the American Academy of Dermatology  , e11DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Facial adenocarcinoma treated with intra-arterial chemotherapy

Facial adenocarcinoma treated with intra-arterial chemotherapy
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,
Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.

Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD 

Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD 
Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker  Chia-Chi Hsu, MD,

Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker  Chia-Chi Hsu, MD,
Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 
Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Similar presentations

Ads by Google